Financial
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Kheiron Medical Technologies
HQ United Kingdom · Europe
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Not assessed
Customer rating
No reviews yet
Financial health
Band: Not assessedPrivately held
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Kheiron Medical Technologies found in HSH's search of the last 24 months. Note: Kheiron was acquired by DeepHealth, a RadNet subsidiary, in Oct 2024.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Kheiron Medical Technologies found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, safety notices or clinical safety actions involving Kheiron Medical Technologies or its Mia product found in HSH's search of the last 24 months. The UK National Screening Committee does not currently recommend AI for NHS breast screening.
Contract performance
Mar 2026: A Nature Cancer evaluation of Kheiron's Mia in NHS Grampian breast screening (10,889 women) reported 10.4% more cancers detected; wider UK evaluation is planned through the EDITH trial.
Competitors
No competitors linked yet.